Prothena (PRTA) CEO Gene Kinney granted 520,000 stock options with 2027 vesting

Rhea-AI Filing Summary

Kinney Gene G. reported acquisition or exercise transactions in this Form 4 filing.

PROTHENA CORP PUBLIC LTD CO reported that President and CEO Gene G. Kinney received a grant of stock options covering 520,000 shares on March 3, 2026. These options vest as to 25% of the total shares on March 3, 2027, then in equal monthly installments of 1/48th of the total shares on each monthly anniversary thereafter, subject to his continued employment with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kinney Gene G.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	520,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 520,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kinney Gene G.

(Last) (First) (Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.36	03/03/2026		A		520,000		(1)	03/03/2036	Ordinary Shares	520,000	$0	520,000	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

	/s/ Michael J. Malecek, as Attorney-in-Fact for Gene G. Kinney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PROTHENA (PRTA) report for Gene G. Kinney?

PROTHENA reported that President and CEO Gene G. Kinney received a grant of stock options for 520,000 shares. The options were granted on March 3, 2026 and are held directly, according to the Form 4 filing.

How many stock options did the PROTHENA (PRTA) CEO receive?

Gene G. Kinney received stock options covering 520,000 shares of PROTHENA. This entire amount was reported as acquired in a single derivative transaction dated March 3, 2026, and represents his total options following the transaction.

When do Gene G. Kinney’s PROTHENA (PRTA) stock options start vesting?

The options begin vesting on March 3, 2027, when 25% of the total 520,000 shares vest. After that initial vesting date, additional portions vest in equal monthly installments, contingent on his continued employment.

What is the vesting schedule for the 520,000 PROTHENA (PRTA) stock options?

The options vest 25% of the total 520,000 shares on March 3, 2027. The remaining shares vest in 1/48th increments on each monthly anniversary thereafter, subject to Gene G. Kinney’s continued employment with PROTHENA on each vesting date.

Is Gene G. Kinney’s PROTHENA (PRTA) option grant direct or indirect ownership?

The Form 4 indicates that Gene G. Kinney holds the 520,000 stock options as direct ownership. There is no footnote stating that another entity holds voting or investment authority over these derivative securities.

What transaction code is used for the PROTHENA (PRTA) CEO’s option grant?

The transaction is coded as “A,” described as a grant, award, or other acquisition. It is classified as a derivative security, specifically a stock option with a right to buy shares of PROTHENA common stock.